A novel channelopathy in pulmonary arterial hypertension. - Wikidata - wikimedia - TriplyDB

A novel channelopathy in pulmonary arterial hypertension.

A novel channelopathy in pulmonary arterial hypertension.

http://www.wikidata.org/entity/Q37219463

about

Pulmonary capillary hemangiomatosis: a focus on the EIF2AK4 mutation in onset and pathogenesis Neuronal and Cardiovascular Potassium Channels as Therapeutic Drug Targets: Promise and Pitfalls Complex genetics of pulmonary diseases: lessons from genome-wide association studies and next-generation sequencing The genetics of pulmonary arterial hypertension Molecular Mechanisms of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension Pulmonary arterial hypertension associated with congenital heart disease and Eisenmenger syndrome: current practice in pediatrics Whole-exome sequencing reveals TopBP1 as a novel gene in idiopathic pulmonary arterial hypertension Identification of Rare Variants in ATP8B4 as a Risk Factor for Systemic Sclerosis by Whole-Exome Sequencing.Pancreatic β-cell-specific ablation of TASK-1 channels augments glucose-stimulated calcium entry and insulin secretion, improving glucose tolerance.Pulmonary arterial hypertension: the clinical syndrome.Pediatric pulmonary arterial hypertension.Sex differences in the pulmonary circulation: implications for pulmonary hypertension Update in pulmonary vascular diseases 2013.Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting β agonist treatment in a multiethnic asthma population: a genetic study.Pulmonary arterial hypertension: Specialists' knowledge, practices, and attitudes of genetic counseling and genetic testing in the USA Future breakthroughs in the genetics of pulmonary arterial hypertension.Effects of long-term averaging of quantitative blood pressure traits on the detection of genetic associations Functional prostacyclin synthase promoter polymorphisms. Impact in pulmonary arterial hypertension.Heritable forms of pulmonary arterial hypertension.Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Genetics of pulmonary hypertension Gain-of-function mutation in TASK-4 channels and severe cardiac conduction disorder.Progress in the diagnosis and management of pulmonary hypertension in children.Trans-ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation.Implications of population structure and ancestry on asthma genetic studies.Interleukin 13- and interleukin 17A-induced pulmonary hypertension phenotype due to inhalation of antigen and fine particles from air pollution Molecular aspects of structure, gating, and physiology of pH-sensitive background K2P and Kir K+-transport channels.Building the case for novel clinical trials in pulmonary arterial hypertension Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertension.The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes.Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension.Rescuing the BMPR2 signaling axis in pulmonary arterial hypertension Two-pore domain potassium channels in the adrenal cortex.Current clinical management of pulmonary arterial hypertension Mutation in BMPR2 Promoter: A 'Second Hit' for Manifestation of Pulmonary Arterial Hypertension?High Frequency of Pulmonary Hypertension-Causing Gene Mutation in Chinese Patients with Chronic Thromboembolic Pulmonary Hypertension Accurate genetic diagnosis of Finnish pulmonary arterial hypertension patients using oligonucleotide-selective sequencing.Statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute.Breathing Stimulant Compounds Inhibit TASK-3 Potassium Channel Function Likely by Binding at a Common Site in the Channel Pore.TASK-1 potassium channel is not critically involved in mediating hypoxic pulmonary vasoconstriction of murine intra-pulmonary arteries.A burden of rare variants in BMPR2 and KCNK3 contributes to a risk of familial pulmonary arterial hypertension.

P2860

6a7e0a220c950aae60a73018c80c7ff410ddc616

P248

Q26795562-FF36F993-78AF-4752-AC10-6EA3625A8C2B Q26798018-0761597D-4601-4CE3-9B80-06576B59FC41 Q26864326-C0DD720A-D790-4974-9473-5022955C61E0 Q27027507-1A9E560E-401A-4046-A8B3-3B82823898B5 Q28067063-A8235C7A-FD18-48B5-8603-5680B949348E Q28085572-80B19389-90A3-4AC0-8551-E05C0B343E84 Q28237461-5672FA70-DF96-47F0-A827-D34904ABA3B6 Q28397539-145376A7-8B17-4E72-B9C8-C37120506FAD Q30370626-52050E45-8DF0-4DC8-910A-8EDB0175427C Q30583630-7E8F74B1-6995-4A47-A553-A38BF0F3AF2B Q33163446-D8745B05-AA5A-423A-8B06-6210A17FF92F Q33568826-8D81D00A-A60F-4435-87CE-FBD8740FF2E0 Q33732209-9A0B6633-CB8F-4136-9A5D-EF6F6339EBA7 Q33739535-4430E544-0BE6-4FA9-88B0-7A50AC72C4AC Q33788468-F78B81BE-B07D-42EC-A944-CB01C4F96880 Q33806126-BF2F28D4-5253-49CB-99DB-B363361FCF00 Q33858783-D771149D-8A90-4969-8FC3-3EAEE3B1EA8A Q33901696-E0EC4CDE-EAB6-4278-993D-013E0BEFE5F9 Q33915567-2A6850A7-8B4B-45D6-91E7-1D4A1B2FA5C2 Q33965854-9FE05D8C-7FD4-4343-AC0C-F0A2A14861EA Q33991477-DA2B672C-94F1-4A1C-BD3D-F55867DAFA05 Q34479289-3D9BC823-9645-4FDB-BE51-52A736AB05C1 Q34495057-81F1941C-6D1D-4706-BD91-B7D247235F8D Q34781489-11E3A93B-8F5F-4F6D-958B-5FA7E595715B Q34782588-2574EE33-EBA4-4690-9F2C-485A8C02CA8B Q34800154-46D809C9-7396-45B4-8EB6-5C94D24B6B3B Q35005853-8CE7FF23-CC31-4FDF-809D-806A005B4599 Q35019516-E890FBC1-6BB8-4B10-BF17-BE4A6AD0F014 Q35115789-81288595-1BC3-4712-8C52-DEA159CD46FD Q35140747-0E6BA549-7095-496B-B8F0-36B38D1FE4B6 Q35410950-D78B219E-DE25-4CE5-9B6F-4FE39C964068 Q35597757-3EF3B908-9F02-4342-B0F7-55F77AF69033 Q35673783-97958C88-22E9-449A-A453-73A30B84E1AD Q35689320-49C16EF9-6832-4A21-B535-DDF8CDDA0B0C Q35907239-CFFDCE70-0C0A-492E-9FC0-B34BBCF7D723 Q35907757-FEFEA297-BD63-4EB3-9E8B-4F385A0044ED Q36016478-28295E4D-2C33-448C-A1E6-7884FB6B1DED Q36186112-B9850D26-6E33-4BBF-A51F-CD06AFE107A6 Q36310811-DF88343B-D771-4D90-A938-8D51B27A292E Q36340262-B9B67CAC-0B8C-4CAE-ACAB-2210EDB36E79

P2860

A novel channelopathy in pulmonary arterial hypertension.

http://www.wikidata.org/entity/Q37219463

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

A novel channelopathy in pulmonary arterial hypertension.

@en

A novel channelopathy in pulmonary arterial hypertension.

@nl

type

label

A novel channelopathy in pulmonary arterial hypertension.

@en

A novel channelopathy in pulmonary arterial hypertension.

@nl

prefLabel

A novel channelopathy in pulmonary arterial hypertension.

@en

A novel channelopathy in pulmonary arterial hypertension.

@nl

P1433

Q37219463-7A52DFC4-6E69-4FB4-8447-3FB504C335A7

P1476

Q37219463-E4B62ECC-7548-488E-AF52-95F239763FB4

P2093

Q37219463-22129EA1-421C-4B0A-A7CE-2248CBA307D3

Q37219463-23F660D4-6888-4C7D-A38B-A517BD2634C6

Q37219463-36C73B5C-4496-441B-BE9B-2F3B6B36D0B4

Q37219463-3C2AC42C-034F-48EA-811D-B382E9EDB220

Q37219463-61189647-CB28-4E7F-A073-8EA9A194E5C0

Q37219463-62E0A790-986F-4B2F-B499-C493A2A5EDD8

Q37219463-6E5620F9-3E36-492E-BE5D-556E04832DB0

Q37219463-910F6F4C-010F-4D00-936A-6C4253CADEDE

Q37219463-C7709A82-16EF-476D-A17E-820B4D47FB6A

Q37219463-C81CEF0C-B097-48BE-A1B1-18B91A8DECE1

P2860

Q37219463-0ECB972E-2978-4840-ADA5-91BFACAC61BE

Q37219463-118E48B9-947E-411C-B977-E96712B5A315

Q37219463-1A27846F-FD29-405D-97FA-6D09C254487B

Q37219463-1C3684CA-0AE7-4C50-814C-7DD16C97A989

Q37219463-228501EF-856C-461D-9F7B-F64C890ECB38

Q37219463-2D89639E-762C-4ECD-A514-71980FFEFB65

Q37219463-3E9341C0-3921-467E-9C26-551CBE9FE5E7

Q37219463-44FE3C17-8F27-4C68-985B-45060C807D48

Q37219463-4D5DD400-4D04-47DA-8E35-EEF5E32594B8

Q37219463-5025A5FD-FDD0-413F-B593-19CDE4F380F3

P304

Q37219463-9A3F4AD1-0F2F-4786-81F0-271A44131A11

P31

Q37219463-B2839C6B-DFB8-4341-8B03-0F088AB8A30B

P356

Q37219463-CD7C83A3-701E-4D22-9343-902A66447529

P407

Q37219463-817C9AF9-51AB-4374-9F2D-6CFA89A7825C

P433

Q37219463-81368064-D83C-4AC2-B1DB-CF0167490E0D

P478

Q37219463-F1C8A199-FFB8-44FE-BBC1-82650857A27A

P50

Q37219463-3E9AE3AE-8CA7-425F-8DEB-404AB9837BB9

Q37219463-48D00C31-D6C4-4E4B-993E-7C4E4A41A57E

Q37219463-693C614B-54A1-40E6-8186-C1FFEA9045C3

Q37219463-AFF97486-0C9B-4578-8B97-6A000EADC6C2

P577

Q37219463-AE939AAC-A3D1-44CF-A3CB-E3F3C6D2194E

P5875

Q37219463-07344546-1C12-46AB-8E32-79A28CAE93FE

P698

Q37219463-52746D91-142A-4A3E-A8D1-7B94C7F2BF61

P921

Q37219463-2F7156D3-84FB-4FBB-B8B9-47D85A03365E

P932

Q37219463-54DDFFB1-251D-43A3-912E-D9D79236F13C

P356

P1433

The New England Journal of Medicine

P1476

A novel channelopathy in pulmonary arterial hypertension.

@en

P2093

Alain Borczuk

http://www.w3.org/2001/XMLSchema#string

Barbara Girerd

http://www.w3.org/2001/XMLSchema#string

Danilo Roman-Campos

http://www.w3.org/2001/XMLSchema#string

Eric D Austin

http://www.w3.org/2001/XMLSchema#string

Florent Soubrier

http://www.w3.org/2001/XMLSchema#string

James E Loyd

http://www.w3.org/2001/XMLSchema#string

Kevin S Sampson

http://www.w3.org/2001/XMLSchema#string

Lijiang Ma

http://www.w3.org/2001/XMLSchema#string

Marine Germain

http://www.w3.org/2001/XMLSchema#string

Mélanie Eyries

http://www.w3.org/2001/XMLSchema#string

P2860

Cloning and expression of a novel pH-sensitive two pore domain K+ channel from human kidney

Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia

Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1

Inhalational anesthetics activate two-pore-domain background K+ channels

An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation

Analysis of ALK-1 and endoglin in newborns from families with hereditary hemorrhagic telangiectasia type 2.

Distribution analysis of human two pore domain potassium channels in tissues of the central nervous system and periphery.

Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene.

Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2.

TASK1 (K(2P)3.1) K(+) channel inhibition by endothelin-1 is mediated through Rho kinase-dependent phosphorylation

P304

351-361

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1211097

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

369

http://www.w3.org/2001/XMLSchema#string

P50

David-Alexandre Trégouët

Erika Berman-Rosenzweig

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

251876375

http://www.w3.org/2001/XMLSchema#string

P698

23883380

http://www.w3.org/2001/XMLSchema#string

P921

arterial hypertension

P932

3792227

http://www.w3.org/2001/XMLSchema#string